Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02669862 · ClinicalTrials.gov registry record · Phase 2
A Study of A-101 Solution in Subjects With Common Warts.
A Phase 2 study of Common Warts, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
- 1
- Study location
NCT02669862 is a Phase 2 study of Common Warts that has completed, run by Aclaris Therapeutics. The registered enrollment target is 98 participants, below the 125-participant average among 3 other Common Warts trials with a reported enrollment target (22% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02669862, a Phase 2 study of Common Warts, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, vehicle-controlled, parallel-group study with 3 treatment groups.
Conditions Studied
Interventions
- DRUG A-101 Solution 40
- DRUG A-101 Solution 45
- DRUG Vehicle Solution
Study Locations (1)
Pennsylvania
- Aclaris Therapeutics, Inc. - Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2015-12-21 |
| Est. Completion | 2016-09-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02669862
The ClinicalTrials.gov registry entry for NCT02669862 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 125-participant average among 3 other Common Warts trials with a reported enrollment target (22% lower). The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Common Warts appearing as the primary indexed condition, and to 3 interventions - of which A-101 Solution 40 is the first listed.
NCT02669862 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02669862 about?
NCT02669862 is a clinical study titled "A Study of A-101 Solution in Subjects With Common Warts.". This is a randomized, double-blind, vehicle-controlled, parallel-group study with 3 treatment groups.
What is the current status of trial NCT02669862?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2015-12-21. Estimated completion is 2016-09-16.
What conditions does trial NCT02669862 study?
This clinical trial studies the following conditions: Common Warts.
What interventions are being tested in trial NCT02669862?
The interventions under investigation include: A-101 Solution 40 (DRUG), A-101 Solution 45 (DRUG), Vehicle Solution (DRUG).
Who is sponsoring clinical trial NCT02669862?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02669862 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Common Warts
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.